In February, Basilea announced a strategic refocusing on its core anti-infective business and is exploring strategic options for its oncology assets. Strong FY21 results were driven by key anti-infective assets Cresemba and Zevtera, which collectively contributed CHF131.4m to Basilea’s revenue (up 18% y-o-y). Global Cresemba sales were US$324m in FY21, resulting in significantly increased royalty and milestone payments. Management envisages sustainable profitability and positive operating cash f ....
04 May 2022
Basilea Pharmaceutica - Renewed focus on anti-infectives
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - Renewed focus on anti-infectives
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
04 May 2022 -
Author:
Soo Romanoff -
Pages:
20
In February, Basilea announced a strategic refocusing on its core anti-infective business and is exploring strategic options for its oncology assets. Strong FY21 results were driven by key anti-infective assets Cresemba and Zevtera, which collectively contributed CHF131.4m to Basilea’s revenue (up 18% y-o-y). Global Cresemba sales were US$324m in FY21, resulting in significantly increased royalty and milestone payments. Management envisages sustainable profitability and positive operating cash f ....